【交银国际：百济神州指引今年经营利润转正 维持“买入”评级】交银国际报告称，百济神州核心产品放量迅速，泽布替尼美国新患份额跃居首位。去年第四季销售收入 11.18 亿美元，同比增长 77%，其中泽布替尼 8.28 亿美元，环比增 20%，美国销售 6.16 亿美元，环比增 22%。全年经调整经营利润转正至 4536 万美元。公司指引 2025 全年收入 49 至 53 亿美元，GAAP 经营费用 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.